NASDAQ$IMUX
Immunic Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Immunic reported financial results for the year ended December 31, 2022 and provided a corporate update.
Immunic reported its year end 2022 financial results, highlighting the progress of vidofludimus calcium for multiple sclerosis treatment and upcoming data readouts from clinical trials. The company's cash reserves are expected to fund operations into the fourth quarter of 2024.
- Advanced vidofludimus calcium for multiple sclerosis (MS) treatment.
- Anticipate interim analysis of phase 2 CALLIPER trial in progressive MS in the second half of 2023.
- Expect data from the interim analysis of the phase 3 ENSURE program late next year.
- IMU-856 shows potential as a first-in-class oral celiac disease therapy.
Headline financials
Revenue & EPS history
Immunic · Revenue · Quarterly
$0
Forward guidance
Immunic anticipates several clinical milestones in the near future, including data readouts from ongoing trials for vidofludimus calcium and IMU-856.
Tailwinds
- Interim analysis of phase 2 CALLIPER trial of Vidofludimus Calcium in Progressive Multiple Sclerosis expected in the second half of 2023
- Initial Results From Ongoing Part C of Phase 1 Clinical Trial of IMU-856 in Celiac Disease Expected Mid-2023
- The CALLIPER trial is designed to corroborate the neuroprotective potential of vidofludimus calcium
- Design of the ENSURE program gives Immunic a straightforward path toward potential regulatory approval in relapsing MS
- Vidofludimus calcium has the potential to be a unique treatment option targeted to the biology of MS, differentiated by its combined anti-inflammatory, antiviral and neuroprotective effects
Headwinds
- The COVID-19 pandemic
- Increasing inflation
- Impacts of the Ukraine – Russia conflict on planned and ongoing clinical trials
- Risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations
- The availability of sufficient financial and other resources to meet business objectives and operational requirements
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
+0.1%
Avg return
Earnings day
-0.1%
Avg return
5 days after
-4.5%
Avg return
30 days after
37%
17 / 46 earnings
Positive
+37.0%
Q2 2022
Best reaction
-16.4%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -3.8% | -1.7% | +15.5% | |
| Q3 2025 | -6.3% | +0.0% | -18.2% | |
| Q4 2024 | -2.1% | -28.1% | -22.7% | |
| Q1 2025 | -4.8% | -7.8% | -26.4% | |
| Q3 2024 | +0.0% | -2.5% | +8.5% | |
| Q1 2024 | -10.1% | -9.1% | -10.9% | |
| Q4 2023 | -4.7% | +8.6% | +3.1% | |
| Q3 2023 | +3.2% | +9.4% | +50.7% | |
| Q2 2023 | -6.9% | -8.8% | -20.4% | |
| Q1 2023 | -2.8% | -5.0% | -3.9% | |
| Q4 2022 | +0.0% | +4.8% | -21.7% | |
| Q3 2022 | -11.1% | -12.3% | -20.5% | |
| Q2 2022 | +37.0% | +29.0% | +16.7% | |
| Q1 2022 | +0.4% | +12.1% | -25.1% | |
| Q4 2021 | -9.4% | -3.2% | -0.4% | |
| Q3 2021 | +2.1% | +1.1% | -16.7% | |
| Q2 2021 | +21.7% | +17.1% | +25.5% | |
| Q1 2021 | -8.3% | -8.1% | -2.8% | |
| Q4 2020 | +0.5% | -1.7% | -5.7% | |
| Q3 2020 | +4.4% | +7.3% | +10.7% | |
| Q2 2020 | +27.9% | +8.7% | -11.6% | |
| Q1 2020 | +18.3% | +20.3% | +53.9% | |
| Q4 2019 | -16.4% | -19.3% | +19.3% | |
| Q3 2019 | -6.4% | -6.2% | -17.3% | |
| Q2 2019 | +0.4% | +4.6% | +6.4% | |
| Q1 2019 | +7.1% | -16.1% | -58.8% | |
| Q4 2018 | -11.1% | -8.3% | -17.8% | |
| Q3 2018 | -7.0% | -9.9% | -18.9% | |
| Q2 2018 | -2.8% | +6.8% | -17.0% | |
| Q1 2018 | +0.9% | +2.7% | -11.7% | |
| Q4 2017 | -6.5% | +2.6% | +0.0% | |
| Q3 2017 | -4.5% | +4.5% | -7.3% | |
| Q2 2017 | +17.3% | +11.5% | +17.3% | |
| Q1 2017 | -4.0% | -17.3% | -17.3% | |
| Q4 2016 | -1.2% | +1.2% | -11.6% | |
| Q3 2016 | -1.0% | +8.6% | -4.8% | |
| Q2 2016 | +1.3% | -0.5% | -5.8% | |
| Q1 2016 | +3.9% | — | — | |
| Q4 2015 | -4.9% | — | — | |
| Q3 2015 | -3.9% | — | — | |
| Q2 2015 | +15.8% | — | — | |
| Q1 2015 | -5.6% | — | — | |
| Q4 2014 | -9.0% | — | — | |
| Q3 2014 | +5.0% | — | — | |
| Q2 2014 | -7.2% | — | — | |
| Q1 2014 | -0.1% | — | — | |
| Q2 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro